In patients with anti-nuclear matrix protein 2 (NXP2) antibodies, the classic cutaneous findings of dermatomyositis are often accompanied by symmetric peripheral edema, calcinosis cutis, dysphagia, and myositis in addition to an increased risk of an underlying neoplasm.1 This evidence concerns the gene MORC3 and dermatomyositis.